Xeris Biopharma Holdings, Inc. (XERS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Xeris Biopharma Holdings, Inc. (XERS:NASDAQ), powered by AI.

Current Price
$6.90
P/E Ratio
1998.1
Market Cap
1.1B
Sector
Healthcare
What is the Xeris Biopharma Holdings, Inc. stock price forecast?

Xeris Biopharma Holdings, Inc. is currently trading at $6.90. View real-time AI analysis on Alpha Lenz.

What is Xeris Biopharma Holdings, Inc. insider trading activity?

View the latest insider trading data for Xeris Biopharma Holdings, Inc. on Alpha Lenz.

What is Xeris Biopharma Holdings, Inc.'s P/E ratio?

Xeris Biopharma Holdings, Inc.'s P/E ratio is 1998.1.

Xeris Biopharma Holdings, Inc.

NASDAQ · XERS
$6.90+0.02(+0.29%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Xeris Biopharma Holdings, Inc.'s future dividend policy...
Alpha Chat Insight

Xeris Biopharma Holdings, Inc. trades at a P/E of 1998.1 (premium valuation) with modest ROE of -7.0%. 3Y revenue CAGR of 38.3% highlights clear growth momentum.

Ask for details

Company Overview

Xeris Biopharma Holdings Inc. is a biopharmaceutical company focused on the development and commercialization of innovative solutions utilizing its proprietary technology platforms. The primary function of Xeris is to address critical unmet needs in neurology, gastroenterology, and endocrinology through novel treatments that enhance patient care and convenience. A notable feature of Xeris's offerings is their pre-prepared, ready-to-use formulations that eliminate the need for intravenous or hospital-based care, thus facilitating easier administration and improving patient compliance. The company plays a pivotal role in the healthcare market by reducing the burden of chronic diseases and emergency situations through innovative drug delivery systems. Xeris's impact is particularly significant in sectors such as emergency medicine and chronic disease management, where immediacy and ease of access to medication are crucial. Its proprietary technologies enable the stabilization and reliable delivery of otherwise unstable compounds, significantly enhancing therapeutic outcomes. Headquartered in the United States, Xeris continues to expand its portfolio and global reach, aiming to transform the landscape of patient-centered therapeutics.

CEOMr. John P. Shannon
SectorHealthcare
IndustryBiotechnology
Employees394

Company Statistics

FY 2025

Profile

$1.11BMarket Cap
$291.85MRevenue
0.00Shares Out
394Employees

Margins

85.41%Gross
14.50%EBITDA
8.53%Operating
0.19%Pre-Tax
0.19%Net

Valuation

1998.08P/E
80.86P/B
3.79EV/Sales
29.62EV/EBITDA
39.63P/FCF

Growth (CAGR)

38.33%Rev 3Yr
70.20%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

0.16%ROA
-6.96%ROE
8.39%ROIC

Financial Health

$111.04MCash & Cash Equivalents
$258.80MNet Debt
2701.72%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Xeris Biopharma Holdings, Inc. (ticker: XERS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 394 employees. Market cap is $1.1B.

The current price is $6.9 with a P/E ratio of 1,998.08x and P/B of 80.86x.

ROE is -6.96% and operating margin is 8.53%. Annual revenue is $292M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Xeris Biopharma Holdings, Inc. (XERS) Stock Forecast 2026 $6.90 — Price, Financials & Analyst Targets | Alpha Lenz